Significant reduction in 6-year fragility fracture risk with zoledronate vs placebo for osteopenia

N Engl J Med. 2018 Dec 20;379(25):2407-2416. doi: 10.1056/NEJMoa1808082

Periprosthetic bone loss post-total hip arthroplasty mitigated by bisphosphonate therapy

J Orthop Surg Res. 2018 Sep 4;13(1):225. doi: 10.1186/s13018-018-0918-7

Adherence to weekly oral BP therapy versus quarterly IV BP therapy at varying health literacy level

J Bone Miner Metab. 2018 Sep;36(5):589-595. doi: 10.1007/s00774-017-0867-y

Romosozumab versus placebo, alendronate, and teriparatide for postmenopausal osteoporosis

Climacteric. 2018 Apr;21(2):189-195

Larger BMD gains in osteoporosis patients transitioning to denosumab versus other active controls

Expert Opin Drug Saf. 2018 Apr;17(4):413-428

AAOS2018: Abaloparatide 80ug daily reduces rate of major NVFs in osteoporotic postmenopausal women

Zoledronic Acid, alendronate, and risedronate reduce vertebral, nonvertebral, and hip fracture

Osteoporos Int. 2016 Nov;27(11):3289-3300

Lower incidence of vertebral fracture with romosozumab vs placebo for osteoporosis

N Engl J Med. 2016 Oct 20;375(16):1532-1543

The effect of eldecalcitol on balence and strength in women with osteoporosis

J Bone Miner Metab. 2016 Sep;34(5):547-54

Greater BMD increase with denosumab vs ZOL in patients switching from oral bisphosponates

J Clin Endocrinol Metab. 2016 Aug;101(8):3163-70

Combination therapy improves site-specific BMD vs. teriparatide & denosumab monotherapies

J Clin Densitom. 2016 Jul-Sep;19(3):346-51

Immediate effects on bone metabolism biomarkers noted with resistance training and walking

BMC Musculoskelet Disord. 2016 Jun 8;17(1):254

Comparison of risedronate, alendronate, zoledronate, and ibandronate in those with low BMD

Bone. 2016 Aug;89:52-8

Network meta-analysis of anti-osteoporosis therapies for oral glucocorticoid users

Osteoporos Int. 2016 Jun;27(6):1989-98

Efficacy of combined teriparatide & denosumab vs. single-drug treatment for osteoporosis

J Clin Endocrinol Metab. 2016 May;101(5):2023-30

WCO-IOF 2016: Alfacalcidol (Vit D analogue) vs. cholecalciferol (Vit D) for osteoporosis

Efficacy of zoledronic acid following PLIF in patients with osteoporosis

Osteoporos Int. 2016 Apr;27(4):1469-76

WCO-IOF 2016: Daily subcutaneous abaloparatide vs teriparatide & placebo for osteoporosis

WCO-IOF 2016: Greater BMD increase after 1 year of romosozumab vesus teripratide

WCO-IOF 2016: Denosumab versus zoledronic acid following oral bisphosphonate therapy